加味痛泻要方治疗腹泻型肠易激综合征的临床疗效

Clinical Therapeutic Results of the Jiawei Tongxie Yaofang in the Treatment of Diarrheal Irritable Bowel Syndrome

为观察加味痛泻要方治疗腹泻型肠易激综合征（IBS）的临床疗效，我们将100例符合罗马Ⅲ诊断标准的IBS患者随机分为治疗组和对照组，各50例。治疗组采用加味痛泻要方治疗；对照组则以得舒特治疗，同时口服培菲康调节肠道菌群。结果显示，治疗组痊愈10例，显效17例，有效18例，无效5例，总有效率为90％（45／50）；对照组痊愈7例，显效13例，有效15例，无效15例，总有效率为70％（35／50）。治疗组疗效明显优于对照组，P〈0．05。且治疗组在腹痛、泄泻症状改善，以及不良反应方面均明显优于对照组。结果表明，加味痛泻要方治疗IBS疗效优于单纯西药治疗。

For the objecitve of observing the clinical effect of Jiawei Tongxie Yaofang（TY,prescription for diarrhea with pain） ,one hundred patients with IBS were randomized into two groups,50 cases received the therapy（the study group）, while the other 50 cases received Dicetel and Bifid to regulate intestinal flora （the control group）. As results, 10 cases were cured, 17 were markedly improved, 18 were improved and 5 had no improvement, the general improvement rate was 90. 0% （45/50） in the study group; whlie in the control group, the respective number of patients was 7,13,15 and 15 respectively, the general improvement rate was 70.0% （35/50） ,the therapentic efficacy in study group was better than that in control group （ P 〈0.05） ,while the abdominal pain,diarrhea and side reaction of study group were better than that in control group. It is concluded that TY is better in the treatment of IBS than Western drug alone.